U.S drug giant Pfizer Inc has announced that it has combined operations with Wyeth following the closing of the acquisition recently.
In a statement, the company said: “Pfizer is now a more diversified health care company, with product offerings in human, animal, and consumer health, including vaccines, biologics, small molecules and nutrition across the developed and emerging markets. It has medicines in numerous growing therapeutic areas, a robust pipeline, premier scientific and manufacturing capabilities and a leading global presence”.
The company said as a result of the acquisition, it now has a broad and diversified global product portfolio, with leadership in virtually all key high-growth therapeutic areas.
In its statement, the company went on to say: “The combined company has a robust and growing pipeline of biopharmaceutical development projects to help patients in critical areas, including Alzheimer’s disease, oncology, pain, neuroscience, diabetes and inflammation. The combination of top scientists from both companies, as well as leading scientific and manufacturing capabilities, and a global network of proof-of-concept clinical development centres, has greatly enhanced the company’s ability to innovate.
“Pfizer will now operate through its patient-centric business units in human health as well as through its animal health, consumer and nutrition businesses that match the speed and agility of small, focused enterprises with the benefits of a global organisation’s scale and resources”.